NU670 Unit 7 Mood Stabilizer Drug Class Explainer Example

One Shelf Label, Four Different Drugs: A Drug Class Explainer on Lithium, Valproate, Lamotrigine and Carbamazepine for Bipolar Disorder

[Student Name]

Purdue University Global

NU670: PMHNP Neuroscience and Psychopharmacology

Unit 7 Drug Class Explainer

[Instructor Name]

[Date]

The four patients are composite; their details are bracketed. Mechanism grades are the author's.

Why the Label Misleads

"Mood stabilizer" is a clinical label, not a pharmacological one. It groups drugs by what clinicians hope they do, preventing swings in either direction, rather than by a shared chemical action. The four drugs below differ in structure, in the targets they act on, in which phase of bipolar disorder they help most and in what patients experience when taking them. Each is introduced through a composite patient, followed by its proposed mechanisms with an evidence grade and the clinical evidence for its use. Grades use three levels: established in humans, supported in cells or animals but not confirmed in human brain, and speculative.

Lithium: Ms. [A.], 46

Ms. [A.] has bipolar I disorder with three hospitalizations for mania and one serious suicide attempt during a depression. She has taken lithium for [six] years at a level of [0.7] mmol/L. She describes a fine tremor, thirst and a sense of being "a little flatter" than before, which she accepts because she has not been hospitalized since starting it.

Proposed mechanisms. For many years, lithium's effect was attributed to inhibition of inositol monophosphatase, depleting the inositol that neurons need for certain signaling pathways. Klein and Melton showed in frog embryos that complete inhibition of that enzyme did not reproduce lithium's effects on development, and that lithium directly inhibits glycogen synthase kinase-3 beta, a kinase involved in cell fate and many other processes (Klein & Melton, 1996). Both mechanisms remain under study. Grade: supported in cells and animals; how either produces mood stability in the human brain is not established.

Clinical evidence. In the BALANCE trial, lithium alone or combined with valproate prevented new mood episodes better than valproate alone in bipolar I disorder over up to two years (BALANCE Investigators and Collaborators, 2010). A meta-analysis of [48] randomized trials found lithium reduced suicides compared with placebo, with an odds ratio of [0.13] (Cipriani et al., 2013). For Ms. A., the reason to stay on lithium is not a known mechanism but a known outcome: fewer episodes and fewer deaths by suicide.

Valproate: Mr. [B.], 34

Mr. [B.] has bipolar I disorder with mostly manic episodes, often mixed with irritability. He started valproate during his last hospitalization because it could be loaded quickly. He has gained [9] kg in a year and has some hair thinning. He prefers it to lithium, which he tried once, because he does not need to drink so much water or have levels checked as often.

Proposed mechanisms. Valproate raises brain concentrations of the inhibitory transmitter gamma-aminobutyric acid and blocks certain sodium channels, which accounts for its anticonvulsant effects. Phiel and colleagues showed that valproic acid directly inhibits histone deacetylase at therapeutic concentrations in cultured cells, changing gene expression, and proposed this as a possible explanation for both its birth defects and its effects in bipolar disorder (Phiel et al., 2001). Grade: established in cells for the enzyme effect; the link to mood is speculative.

Clinical evidence. Valproate is effective for acute mania. For long-term prevention it was inferior to lithium in the BALANCE trial (BALANCE Investigators and Collaborators, 2010). Its risk to a fetus limits its use in women who could become pregnant.

Lamotrigine: Ms. [C.], 29

Ms. [C.] has bipolar II disorder with long depressions and brief hypomanias. She takes lamotrigine [200] mg daily, reached over [six] weeks of slow titration. She reports almost no side effects and says it has "taken the floor out from under" her depressions without making her feel sedated.

Proposed mechanisms. Lamotrigine blocks voltage-gated sodium channels and is thought to reduce the release of glutamate. Grade: the channel effect is established in cells; how this prevents depression but not mania is not explained.

Clinical evidence. In an [18]-month maintenance trial of [463] stabilized patients with bipolar I disorder, both lamotrigine and lithium held off the need for added treatment longer than placebo did; only lamotrigine separated from placebo on the time to a new depression, whereas lithium's separation came mainly on mania (Calabrese et al., 2003). That pattern matches Ms. [C.]'s experience and explains why lamotrigine is chosen for patients whose illness is dominated by depression. The slow titration is required because of the risk of serious rash.

Carbamazepine: Mr. [D.], 52

Mr. [D.] has bipolar I disorder and did not tolerate lithium, which caused a worsening of his psoriasis, or valproate, which raised his liver enzymes. He takes extended-release carbamazepine. He needed to change two other medications because carbamazepine sped up their breakdown.

Proposed mechanisms. Like lamotrigine, carbamazepine blocks voltage-gated sodium channels. Grade: established in cells; the path from channel to mood stability is speculative. Its strong induction of liver enzymes is established in humans and explains Mr. [D.]'s drug interactions, including with oral contraceptives and many other medicines.

Clinical evidence. Carbamazepine has evidence for acute mania, and it is generally used for maintenance after first-line options have failed or were not tolerated.

What the Comparison Shows

Two sodium channel blockers, a drug that inhibits a kinase and another that inhibits an enzyme controlling gene expression: at the level of mechanism, the four have little in common. At the level of patient experience they differ just as much, from lithium's thirst and tremor to valproate's weight gain, lamotrigine's near absence of side effects apart from rash risk, and carbamazepine's interactions. Where they overlap is in the outcome clinicians want, and even there they differ by phase: lithium protects most against mania and suicide, lamotrigine against depression. For a student learning the class, the useful summary is therefore a grid of outcomes by phase and side effects by patient, not a single story about how mood stabilizers work. Ms. [A.], Mr. [B.], Ms. [C.] and Mr. [D.] ended up on different drugs for reasons that had almost nothing to do with receptors and almost everything to do with their episodes, their bodies and their other medicines.

Implications for Practice

The clinical choice among these drugs should rest on outcome evidence matched to the patient: the pattern of episodes, suicide risk, pregnancy potential, other medications and tolerance of side effects. Mechanistic stories can help explain why the drugs differ, but they should not be presented to patients as settled science. When Ms. [A.] asks how lithium works, the honest answer is that researchers have strong leads, and that the reason to take it is that it works for people like her.

References

BALANCE Investigators and Collaborators. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. The Lancet, 375(9712), 385-395. https://doi.org/10.1016/S0140-6736(09)61828-6

Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., & DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. The Journal of Clinical Psychiatry, 64(9), 1013-1024. https://doi.org/10.4088/JCP.v64n0906

Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ, 346, Article f3646. https://doi.org/10.1136/bmj.f3646

Klein, P. S., & Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences, 93(16), 8455-8459. https://doi.org/10.1073/pnas.93.16.8455

Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry, 276(39), 36734-36741. https://doi.org/10.1074/jbc.M101287200